Den Europæiske Union -
dansk -
EMA (European Medicines Agency)
lextemy
mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiske midler - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
eltroxin 100 mikrogram tabletter
aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 100 mikrogram
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
everolimus "stada" 10 mg tabletter
stada arzneimittel ag - everolimus - tabletter - 10 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
everolimus "stada" 5 mg tabletter
stada arzneimittel ag - everolimus - tabletter - 5 mg
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
eltroxin 100 mikrogram tabletter
paranova danmark a/s - levothyroxinnatrium - tabletter - 100 mikrogram
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
medithyrox 100 mikrogram tabletter
uni-pharma kleon - levothyroxinnatrium - tabletter - 100 mikrogram
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
medithyrox 25 mikrogram tabletter
uni-pharma kleon - levothyroxinnatrium - tabletter - 25 mikrogram
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
medithyrox 50 mikrogram tabletter
uni-pharma kleon - levothyroxinnatrium - tabletter - 50 mikrogram
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
medithyrox 75 mikrogram tabletter
uni-pharma kleon - levothyroxinnatrium - tabletter - 75 mikrogram
Den Europæiske Union -
dansk -
EMA (European Medicines Agency)
bavencio
merck europe b.v. - avelumab - neuroendocrine tumorer - andre antineoplastiske midler, monoklonale antistoffer - bavencio er indiceret som monoterapi til behandling af voksne patienter med metastatisk merkel cellecarcinom (mcc). bavencio i kombination med axitinib er angivet for den første linje behandling af voksne patienter med fremskredent renalcellecarcinom (rcc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.